VARIATION IN THE HOSPITAL-LEVEL USE OF A MEDICAL MANAGEMENT STRATEGY ACROSS U.S. HOSPITALS FOR PATIENTS WITH NSTEMI AND MULTIVESSEL CORONARY ARTERY DISEASE DETECTED DURING INHOSPITAL ANGIOGRAPHY  by Harskamp, Ralf E. et al.
Quality of Care and Outcomes Assessment
E1498
JACC March 12, 2013
Volume 61, Issue 10
variaTion in The hospiTal-level use of a medical managemenT sTraTegy across u.s. 
hospiTals for paTienTs wiTh nsTemi and mulTivessel coronary arTery disease deTecTed 
during inhospiTal angiography
Poster Contributions
Poster Sessions, Expo North
Saturday, March 09, 2013, 10:00 a.m.-10:45 a.m.
Session Title: Appropriateness and Gaps in Care
Abstract Category: 28. Quality of Care and Outcomes Assessment
Presentation Number: 1116-113
Authors: Ralf E. Harskamp, Tracy Wang, Deepak Bhatt, Stephen Wiviott, Ezra Amsterdam, Shuang Li, Laine Thomas, Robbert de Winter, Matthew Roe, 
Duke Clinical Research Institute, Durham, NC, USA
Background: Patients with NSTEMI and multi-vessel disease (MVD) identified during coronary angiography face a high-risk of mortality when 
treated with a medical management strategy (MMS) compared with revascularization.
methods: We evaluated the use of MMS for 42,535 NSTEMI patients with 3-vessel disease (3-VD) or left main disease (LMD) during angiography 
at 423 hospitals participating in the ACTION Registry–GWTG from 2007-2012. Patients with prior CABG surgery were excluded, as revascularization 
options are limited. A total of 316 hospitals (n=41,310 pts) with an adequate volume of patients (≥25 pts) were stratified into tertiles by the use of 
MMS. Differences in characteristics and outcomes were analyzed across tertiles.
results: The yearly percentage of patients with 3-VD/LMD treated with MMS was 17%–19% (p-value=0.08), and the hospital-level percentage varied 
widely (median 17.1%, range: 0.0%–44.8%, p<0.0001). Patient characteristics, predicted mortality risk, inhospital mortality rates, and discharge 
treatments were similar across tertiles (Table). Hospitals in the lowest tertile had the greatest use of both PCI and CABG for patients with MVD.
conclusion: Approximately 20% of patients with NSTEMI and 3-VD/LMD are treated with MMS without revascularization. Since the use of this 
strategy varies widely across U.S. hospitals despite relatively similar hospital-level case mix, these findings suggest that for these patients, there is 
no standard threshold for revascularization.
 
